An interventional study of Green Tea Polyphenolics (EGCG) and Chamomile (Matricaria recutita) in Rheumatoid Arthritis, sponsored by Adel A.Gomaa. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Adel A.Gomaa · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Arthritis, Rheumatoid with a site in Egypt — 35 open to participants now, 36 under way, 9 of them phase 3. Arthritis, Rheumatoid · Egypt.
Among the 88 studies in Arthritis, Rheumatoid with a site in Egypt, this one is the 30th largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2025, is one of 18 with no phase, and was the 48th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →35 of the 88 studies in Arthritis, Rheumatoid with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18–70
Horus University · Sites in Egypt
Ages 18–60
Horus University · Sites in Egypt
Ages 18–60
Horus University · Sites in Egypt
Ages 18–60
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 2010; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 68 across the 56 interventional studies, 98 across the 32 observational. Of the 39 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 88 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Adel A.Gomaa as lead sponsor.
Adel A.Gomaa has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
11 of the studies in Arthritis, Rheumatoid with a site in Egypt that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800351Phase 3Tanta UniversityNicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis | 2027-02 |
| NCT07730723Phase 3Ain Shams UniversityThe Effect of Nicorandil on Rheumatoid Arthritis Patients | 2027-07 |
| NCT07401732Tanta UniversityDysphagia in Rheumatoid Arthritis | 2026-11 |
| NCT07632872Horus UniversityDesloratadine as Adjunct Therapy for Rheumatoid Arthritis | 2026-11 |
| NCT07814989Sohag UniversityWrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis | 2027-01-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 88 studies in Arthritis, Rheumatoid with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is no treatment that could utterly cure Rheumatoid arthritis (RA), but the disease is mainly improved by conventional disease-modifying anti rheumatic drugs. Methotrexate and biological DMARDs as JAK-STAT inhibitors may be used to control and delay the progression of the disease and improve the quality of lives of patients. However, DMARDs have deleterious effects on human health. Several natural products have been reported to exert inhibitory effects on the JAK-STAT signaling pathway, including green tea extract, chamomile extract, and licorice extract.
Rheumatoid arthritis (RA) is a chronic, progressive, systemic autoimmune disease characterized by inflammatory cell infiltration and synovial proliferation, accompanied by progressive damage to articular cartilage and subchondral bone. The prevalence of RA is approximately 3.6% in women and 1.7% in men. Although there is currently no definitive cure for RA, disease activity and progression can be effectively controlled with conventional disease-modifying antirheumatic drugs (DMARDs), including methotrexate, as well as biological and targeted synthetic DMARDs. However, the long-term use of these agents may be associated with various adverse effects, highlighting the need for safe and effective complementary therapeutic approaches.
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway plays an important role in the regulation of inflammatory and immune responses in RA. Activation of this pathway by cytokines, particularly interleukin-6 (IL-6), contributes to the persistence of synovial inflammation and disease activity. Therefore, modulation of the JAK-STAT signaling pathway represents a potential therapeutic approach in RA. Several studies have demonstrated that natural plant-derived compounds and extracts possess immunomodulatory and anti-inflammatory properties and may interfere with the JAK-STAT pathway, thereby reducing the production or signaling of pro-inflammatory cytokines.
Among these natural products, licorice (Glycyrrhiza glabra) contains several bioactive constituents, particularly glycyrrhizin, which has been reported to attenuate inflammatory signaling and inhibit components of the JAK-STAT pathway. Glycyrrhizin has been shown to reduce JAK/STAT signaling and may exert anti-inflammatory effects through modulation of IL-6-related signaling. Similarly, chamomile (Matricaria chamomilla) is rich in flavonoids, including apigenin, which has demonstrated anti-inflammatory and immunomodulatory activities. Apigenin has been reported to inhibit JAK1/2 and STAT3 phosphorylation and to reduce inflammatory cytokine production, supporting its potential role in the modulation of JAK-STAT-mediated inflammatory responses.
Green tea (Camellia sinensis) is another natural product rich in polyphenolic compounds, particularly catechins, with epigallocatechin-3-gallate (EGCG) being one of its major bioactive constituents. Green tea polyphenols have demonstrated anti-inflammatory and immunomodulatory effects and have been reported to interfere with JAK-STAT signaling. EGCG has been shown to suppress JAK1/JAK2 and STAT3 activation and to reduce the production of pro-inflammatory cytokines, including IL-6. These effects suggest that green tea extract may contribute to attenuation of inflammatory responses involved in RA and may have potential as a complementary therapeutic intervention.
Collectively, the reported anti-inflammatory and immunomodulatory properties of green tea, chamomile, and licorice, together with their potential effects on JAK-STAT signaling, provide a rationale for investigating these natural products as complementary therapies in RA. Therefore, the present study aimed to assess the efficacy of selected natural JAK-STAT pathway inhibitors, namely green tea, chamomile, and licorice, as complementary medicine in the treatment of patients with rheumatoid arthritis and to evaluate their potential role in attenuating treatment-related adverse effects.
our Research outcome measures:
Primary (main):
Secondary (subsidiary):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women who are pregnant or breastfeeding.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive two tablet green tea extract each tablet containing 300 mg of extract, equivalent to 90 mg of polyphenols twice daily (resulting in a total daily dose equivalent to 180 mg of green tea polyphenols) for 4 months
Dietary Supplement: Green Tea Polyphenolics (EGCG)
received ChE by steeping two chamomile flower tea bags (2 g per bag) in half a cup of hot water once daily in the evening for 4 months, providing a total daily dose of 40 mg of total flavonoids per 4 g of chamomile flowers for 4 months
Dietary Supplement: Chamomile (Matricaria recutita)
Patients in third group received LE syrup, at a dose of 15 mL three times daily (200 mg licorice extract /day) for 4 months.
Dietary Supplement: Licorice
tablets contained 100 mg of hydroxypropyl methylcellulose (HPMC) for 4 months
Dietary Supplement: Placebo
this group took two GTE tablets with each tablet containing 300 mg of extract, equivalent to 90 mg of polyphenols twice daily (resulting in a total daily dose equivalent to 180 mg of green tea polyphenols) for 4 months
Patients in the second group received ChE by steeping two chamomile flower tea bags (2 g per bag) in half a cup of hot water once daily in the evening for 4 months, providing a total daily dose of 40 mg of total flavonoids per 4 g of chamomile flowers for four months
Patients in third group received LE syrup, at a dose of 15 mL three times daily (200 mg licorice extract /day) for four months.
The placebo tablets contained 100 mg of hydroxypropyl methylcellulose (HPMC) for four months
The change in DAS28 based on Erythrocyte sedimentation rate (DAS28-ESR)
DAS-28 score: a DAS-28 score \> 5.1 indicating high disease activity; 3.2\< DAS-28 score≤5.1 indicates moderate disease activity; 2.6\< DAS-28 score≤3.2 indicates low disease activity; DAS-28 score≤2.6 indicates basic disease remission
Time frame: Before the intervention, 4months after the intervention.
Change in visual analogue scale (VAS
each patient will be asked to indicate his or her current level of pain on 100mm scale.0scale indicate no pain and 100mm indicate worst pain imaginable
Time frame: Before the intervention, and 4 months after the intervention
Determination of synovitis on musculoskeletal ultrasound(MSUS)
Determination of synovitis on musculoskeletal ultrasound
Time frame: Before the intervention, and 4months after the intervention
Determination of Inflammatory cytokines levels: (Tumour necrosis factor α OR Interleukin 6).
laboratory test
Time frame: Before the intervention, and 4months after the intervention
Plan to share: Yes — Data will become available to interested investigators upon submitting a reasonable research request by email to A. Gomaa (a.gomma@aun.edu.eg).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: July, 2025
Access criteria: Data will become available to interested investigators upon submitting a reasonable research request by email to A. Gomaa (a.gomma@aun.edu.eg).
Ran from Apr 2025 to primary completion in Jun 2026, 13 months.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 13 months is below that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jul 2023 → Apr 2025, primary completion Jul 2025 → Jun 2026 and completion Dec 2025 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Epigallocatechin gallate · Matricaria recutita · Glycyrrhiza glabra extract